Navigation Links
Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
Date:10/14/2010

HOBOKEN, N.J., Oct. 14 /PRNewswire/ -- Octapharma USA is accepting applications for the Octapharma 25th Anniversary Grants Program, which supports clinical or pre-clinical research focused on human protein therapies in coagulation disorders, immune therapy, intensive care and emergency medicine. The application deadline is April 1, 2011.

Octapharma AG, one of the largest human protein products manufacturers in the world, launched the Octapharma Grants program last year in celebration of the biopharmaceutical company's 25th anniversary. The company's first ever grants program is only available to researchers based in the United States and is administered by Octapharma USA.

Earlier this year, the Rush Hemophilia & Thrombophilia Center at Rush University Medical Center in Chicago was awarded the first grant in the Octapharma program to support research into blood induced joint damage in hemophilia.

Grant applications are accepted online only at www.octapharmagrants.com.  All grant requests will be evaluated by the Octapharma Grants Committee and grant recipients will be announced shortly afterward. Please visit www.octapharmagrants.com for a complete description of the grants program, including the application and review process.

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma AG is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation for over 27 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam® (immune globulin intravenous [human] 5%), is used to treat disorders of the immune system, and Octapharma's Albumin (Human)® is indicated for the restoration and maintenance of circulating blood volume. Octapharma's wilate® received orphan drug exclusivity from the U.S. Food and Drug Administration (FDA) for the treatment of von Willebrand disease (VWD). Octapharma employs over 4,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, N.J.  Octapharma operates two state-of-the-art production sites licensed by the FDA, providing a high level of production flexibility. For more information, please visit www.octapharma.com.


'/>"/>
SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
2. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
3. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
4. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
5. Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
6. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
7. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
8. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
9. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
10. Cannabis Science Issues Guidance on Its Progress Toward FDA Investigative New Drug Applications For Clinical Trials and Proposed Dividend Payout for Current Shareholders to Receive a New Class of Common Stock
11. Reportlinker Adds Nanobiotechnologies - Applications, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential ... or the "Company") (NASDAQ: ANTH ). Such investors ... by visiting the firm,s site: www.bgandg.com/anth .   ... and/or directors have violated Sections 10(b) and 20(a) of the ... ...
(Date:1/17/2017)... DUBLIN , Jan 17, 2017 Research ... Ingredients/API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, ... CVD) - Global Forecast to 2021" report to their offering. ... The global ... by 2021 from USD 157.95 Billion in 2016, growing at a ...
(Date:1/17/2017)... , Jan. 17, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare , today announced that it ... the strength of the Zimmer Biomet management team. ... will assume the position of President, Americas ... Company. Mr. Delp previously served as Zimmer Biomet,s Vice ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Metro Development Group has ... high speed technology into the fabric of an entire community. A highlight of ... and wellness in a yet-to-be-named, health focused campus. Leading this initiative in partnership ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... education for EMS and firefighting professionals, has released four new continuing education courses ... courses are taught live in an online classroom and meet the requirements of ...
(Date:1/17/2017)... ... ... A prescription medication bottle, pocket knife, luggage and a solar-powered aluminum casting ... Challenge , the Cradle to Cradle Products Innovation Institute has announced. , ... run through early 2018. The challenges are presented by the Institute in partnership with ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... financial planning assistance to families and business professionals throughout central Colorado, is joining ... homeless families. , The Aurora Warms The Night organization is committed to breaking ...
(Date:1/17/2017)... ... January 17, 2017 , ... Seceon , ... threats in real-time, today announced a strategic partnership with TechLab Security, ... other Seceon partners, TechLab Security has become a strategic partner and a value ...
Breaking Medicine News(10 mins):